Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients

Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficu

BenzingaJun 25 04:16

Express News | Corcept Therapeutics Inc - Results Demonstrate a Hypercortisolism Prevalence Rate of 24 Percent in This Patient Population

BreakingsJun 25 04:16

Express News | Corcept Announces Presentation of Results From Prevalence Phase of Catalyst Clinical Trial at American Diabetes Association’s Scientific Sessions

BreakingsJun 25 04:15

What Makes Corcept Therapeutics (CORT) a Good Investment Bet?

Yahoo FinanceJun 19 19:39

6 Analysts Have This To Say About Corcept Therapeutics

During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from bullish to bearish.The table below provides a snapshot of their

BenzingaJun 18 03:00

Corcept Therapeutics Price Target Maintained With a $65.00/Share by Truist Securities

Corcept Therapeutics Price Target Maintained With a $65.00/Share by Truist Securities

Dow JonesJun 17 23:37